The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
ESHRE guideline: recurrent pregnancy loss: an update in 2022
Open accessAbstract
STUDY QUESTION: What are the updates for the recommended management of women with recurrent pregnancy loss (RPL) based on the best available evidence in the literature from 2017 to 2022? SUMMARY ANSWER: The guideline development group (GDG) updated 11 existing recommendations on investigations and treatments for RPL, and how care should be organized, and added one new recommendation on adenomyosis investigation in women with RPL. WHAT IS KNOWN ALREADY: A previous ESHRE guideline on RPL was published in 2017 and needs to be updated. STUDY DESIGN, SIZE, DURATION: The guideline was developed and updated according to the structured methodology for development and update of ESHRE guidelines. The literature searches were updated, and assessments of relevant new evidence were performed. Relevant papers published between 31 March 2017 and 28 February 2022 and written in English were included. Cumulative live birth rate, live birth rate, and pregnancy loss rate (or miscarriage rate) were considered the critical outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on the collected evidence, recommendations were updated and discussed until consensus was reached within the GDG. A stakeholder review was organized after the updated draft was finalized. The final version was approved by the GDG and the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: The new version of the guideline provides 39 recommendations on risk factors, prevention, and investigation in couples with RPL, and 38 recommendations on treatments. These includes 62 evidence-based recommendations—of which 33 were formulated as strong recommendations and 29 as conditional—and 15 good practice points. Of the evidence-based recommendations, 12 (19.4%) were supported by moderate-quality evidence. The remaining recommendations were supported by low (34 recommendations; 54.8%), or very low-quality evidence (16 recommendations; 25.8%). Owing to the lack of evidence-based investigations and treatments in RPL care, the guideline also clearly mentions those investigations and treatments that should not be used for couples with RPL. LIMITATIONS, REASONS FOR CAUTION: The guidelines have been updated; however, several investigations and treatments currently offered to couples with RPL have not been well studied; for most of these investigations and treatments, a recommendation against using the intervention or treatment was formulated based on insufficient evidence. Future studies may require these recommendations to be revised. WIDER IMPLICATIONS OF THE FINDINGS: The guideline provides clinicians with clear advice on best practice in RPL, based on the best and most recent evidence available. In addition, a list of research recommendations is provided to stimulate further studies in RPL. Still, the absence of a unified definition of RPL is one of the most critical consequences of the limited scientific evidence in the field. STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the dissemination of the guideline. The guideline group members did not receive payment. O.B.C. reports being a member of the executive board of the European Society for Reproductive Immunology and has received payment for honoraria for giving lectures about RPL in Australia in 2020. M.G. reports unconditional research and educational grant received by the Centre for Reproductive Medicine, Amsterdam UMC from Guerbet, Merck and Ferring, not related to the presented work. S.L. reports position funding from EXAMENLAB Ltd. and ownership interest by stock or partnership of EXAMENLAB Ltd (CEO). S.Q. reports being a deputy director of Tommy’s National centre for miscarriage research, with payment received by the institution for research, staff time, and consumables for research. H.S.N. reports grants with payment to institution from Freya Biosciences ApS, Ferring Pharmaceuticals, BioInnovation Institute, the Danish ministry of Education, Novo Nordic Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond, and Independent Research Fund Denmark and speakers’ fees for lectures from Ferring Pharmaceuticals, Merck A/S, Astra Zeneca, IBSA Nordic and Cook Medical. She also reports to be an unpaid founder and chairman of a maternity foundation. M.-L.v.d.H. received small honoraria for lectures on RPL care. The other authors have no conflicts of interest to declare. DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgment to each individual presentation, nor variations based on locality and facility type. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. (Full disclaimer available at www.eshre.eu/guidelines.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: recurrent pregnancy loss
The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Nelen, W., Peramo, B., Quenby, S., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy004 · Cited by 1,002
Self-citationA Randomized Trial of Progesterone in Women with Recurrent Miscarriages
Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E. M., Bender Atik, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504927 · Cited by 312
Self-citationdu Fossé, N. A., van der Hoorn, M.-L. P., van Lith, J. M. M., le Cessie, S., & Lashley, E. E. L. O. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa010 · Cited by 276
Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis
Younes, G., & Tulandi, T. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.06.025 · Cited by 268
A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy
Coomarasamy, A., Devall, A. J., Cheed, V., Harb, H., Middleton, L. J., Gallos, I. D., Williams, H., Eapen, A. K., Roberts, T., Ogwulu, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813730 · Cited by 197
Self-citationMicronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence
Coomarasamy, A., Devall, A. J., Brosens, J. J., Quenby, S., Stephenson, M. D., Sierra, S., Christiansen, O. B., Small, R., Brewin, J., Roberts, T. E., et al. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.12.006 · Cited by 163
Self-citationRikken, J. F. W., Kowalik, C. R., Emanuel, M. H., Bongers, M. Y., Spinder, T., Jansen, F. W., Mulders, A. G. M. G. J., Padmehr, R., Clark, T. J., van Vliet, H. A., et al. (2021) · Human Reproduction · doi:10.1093/humrep/deab037 · Cited by 161
Self-citationvan Dijk, M. M., Vissenberg, R., Fliers, E., van der Post, J., van der Hoorn, M., de Weerd, S., Kuchenbecker, W. K., Hoek, A., Sikkema, J. M., Verhoeve, H. R., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00045-6 · Cited by 105
Self-citationYamada, H., Deguchi, M., Saito, S., Takeshita, T., Mitsui, M., Saito, T., Nagamatsu, T., Takakuwa, K., Nakatsuka, M., Yoneda, S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101527 · Cited by 75
The rate of euploid miscarriage is increased in the setting of adenomyosis
Stanekova, V., Woodman, R. J., & Tremellen, K. P. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy011 · Cited by 72
Metadata
- Authors
- The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Mcheik, S., Peramo, B., Quenby, S., Nielsen, H. S., van der Hoorn, M.-L., Vermeulen, N., & Goddijn, M.
- Venue
- Human Reproduction Open
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-12-13
- Volume
- 2023
- Issue
- 1
- Pages
- hoad002-hoad002
- ISSN
- 2399-3529 (ISSN-L)
- OpenAlex
- W4323060114
- Cited by
- 417
- References
- 17
- FWCI
- 24.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ESHRE guideline: recurrent pregnancy loss: an update in 2022. https://app.cochat.ai/papers/10.1093/hropen/hoad002
- The paper
- The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Mcheik, S., Peramo, B., Quenby, S., Nielsen, H. S., van der Hoorn, M.-L., Vermeulen, N., & Goddijn, M. (2022). ESHRE guideline: recurrent pregnancy loss: an update in 2022. Human Reproduction Open. https://doi.org/10.1093/hropen/hoad002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.